Seaport Global Securities reaffirmed their buy rating on shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in a report published on Friday, October 6th, MarketBeat Ratings reports. Seaport Global Securities currently has a $19.00 price objective on the biopharmaceutical company’s stock.
A number of other research firms also recently commented on GLMD. Maxim Group set a $14.00 price objective on shares of Galmed Pharmaceuticals and gave the company a buy rating in a research note on Thursday, October 5th. Zacks Investment Research raised shares of Galmed Pharmaceuticals from a hold rating to a buy rating and set a $8.00 price objective for the company in a research note on Wednesday, August 2nd. HC Wainwright upped their price objective on shares of Galmed Pharmaceuticals from $12.00 to $18.00 and gave the company a buy rating in a research note on Tuesday, August 8th. Finally, ValuEngine raised shares of Galmed Pharmaceuticals from a sell rating to a hold rating in a research report on Saturday, June 17th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $14.75.
Shares of Galmed Pharmaceuticals (NASDAQ:GLMD) opened at 8.12 on Friday. The stock’s 50 day moving average is $8.51 and its 200 day moving average is $6.62. The company’s market capitalization is $99.22 million. Galmed Pharmaceuticals has a 12 month low of $2.78 and a 12 month high of $9.59.
Galmed Pharmaceuticals (NASDAQ:GLMD) last released its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.11. Galmed Pharmaceuticals had a negative net margin of 1,443.98% and a negative return on equity of 141.13%. The business had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.29 million. On average, equities analysts predict that Galmed Pharmaceuticals will post ($0.94) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Given “Buy” Rating at Seaport Global Securities” was originally reported by BBNS and is the sole property of of BBNS. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://baseballnewssource.com/markets/seaport-global-securities-begins-coverage-on-galmed-pharmaceuticals-ltd-glmd/1700833.html.
An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. KCG Holdings Inc. bought a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 20,473 shares of the biopharmaceutical company’s stock, valued at approximately $100,000. KCG Holdings Inc. owned about 0.17% of Galmed Pharmaceuticals at the end of the most recent quarter. Institutional investors own 8.32% of the company’s stock.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with our FREE daily email newsletter.